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Fragile X syndrome (FXS) is the most common inherited cause of intellectual disability. It is most
frequently caused by an abnormal expansion of the CGG trinucleotide repeat (>200 repeats) located in
the promoter of the fragile X mental retardation gene (FMR1), resulting in promoter DNA hypermethylation and gene silencing. Current clinical tests for FXS are technically challenging and labor
intensive, and may involve use of hazardous chemicals or radioisotopes. We clinically validated the
Illumina Inﬁnium HumanMethylation450 DNA methylation array for FXS screening. We assessed
genome-wide and FMR1-speciﬁc DNA methylation in 32 males previously diagnosed with FXS, including
nine with mosaicism, as well as ﬁve females with full mutation, and premutation carrier males (n Z 11)
and females (n Z 11), who were compared to 300 normal control DNA samples. Our ﬁndings
demonstrate 100% sensitivity and speciﬁcity for detection of FXS in male patients, as well as the ability
to differentiate patients with mosaic methylation defects. Full mutation and premutation carrier
females did not show FMR1 methylation changes. We have clinically validated this genome-wide
DNA methylation assay as a cost- and labor-effective alternative for sensitive and speciﬁc screening
for FXS, while ruling out the most common differential diagnoses of FXS, Prader-Willi syndrome, and
Sotos syndrome in the same assay. (J Mol Diagn 2016, 18: 834e841; http://dx.doi.org/10.1016/
j.jmoldx.2016.06.005)

Fragile X syndrome [FXS; Online Mendelian Inheritance
in Man (OMIM) 300624] is the most common inherited
cause of intellectual disability, and is one of the most
frequently ordered constitutional genetic tests.1 The
features of FXS include moderate to severe mental
retardation, macroorchidism, and distinct facial features.
The most common cause of FXS is an abnormal expansion in the number of trinucleotide CGG repeats located
in the 50 untranslated region of the fragile X mental
retardation gene (FMR1) at Xq27.3. Large CGG expansions result in DNA hypermethylation and, consequently,
inhibition of FMR1 transcription. However, other mutational mechanisms, such as deletions of FMR1, can cause
FXS.2 Both mechanisms result in deﬁciency of the gene
product, the fragile X mental retardation protein, which is

an RNA binding protein that regulates protein synthesis in
dendrites.3
Depending on the number of CGG repeats, four main
types of alleles are deﬁned, which correlate with different
clinical manifestations.3,4 Normal alleles have up to 44
repeats, premutation (PM) alleles have 55 to 200 repeats,
and full mutation (FM) alleles contain >200 repeats. In
addition, alleles containing 45 to 54 repeats are commonly
referred to as being in a gray zone, and are precursors for
PM alleles. As expected for an X-linked disorder, full
Supported in part by Illumina Inc. (B.S.) and by the South Carolina
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mutations are penetrant in all males, who are also the index
probands in families with fragile X. The physical and
behavioral features seen in males with FXS have been
reported in females heterozygous for the full mutation, but
with low penetrance and mild expressivity. The lower
penetrance in females is explained by two copies of
X chromosome and/or nonrandom X inactivation.5 Interestingly, mosaicism for the methylated FM and an unmethylated premutation account for >40% of affected males
who demonstrate an atypical mild clinical manifestation of
the disease.6,7 Premutation alleles are not hypermethylated
and do not result in FXS-related features, but can in some
patients cause the fragile Xeassociated tremor/ataxia
syndrome, which is characterized by late-onset progressive
cerebellar ataxia and intention tremor.8,9 Also, approximately 20% of premutation carrier females may develop
primary ovarian insufﬁciency, which is deﬁned as cessation
of menses before age 40 years.10 However, females carrying
a premutation may transmit a full mutation allele to their
children. The expansion of premutation to full mutation
alleles occurs during transmission of the maternal X chromosome, but not the paternal X chromosome, to the
offspring.11
The conﬁrmation of a FXS diagnosis at a molecular
level is technically complex. Current guidelines are based
on the characterization of trinucleotide (CGG) repeat
number related to allele size, as well as DNA methylation.1 Two main approaches that are commonly used in
clinical laboratories include the PCR and Southern blot
analysis,12e14 using the FMR1 probe ﬁrst characterized by
Rousseau et al13 in 1991. Ampliﬁcation by PCR using
primers ﬂanking the CGG repeat regions allows the
identiﬁcation of the approximate number of repeats present in each allele. This PCR approach has several limitations. Most signiﬁcantly, alleles with a large number of
repeats can be difﬁcult to amplify and may fail to be
detected by a PCR-based approach. Furthermore, ampliﬁcation may favor the smaller allele and skew the relative
ratio of normal to abnormal alleles. For example, a female
with one normal allele and one large nonampliﬁable
mutant allele could appear to only have the normal allele.1
Similarly, male patients who are mosaics for a premutation along with a full mutation could appear to have
only the premutation. Southern blotting is often used in
parallel with PCR analysis to better characterize the patients with expanded alleles in the full mutation range.
FMR1 analysis by Southern blot enables the detection of
all allele size ranges, but cannot be used for precise
expansion sizing and assessment of the methylation status. Furthermore, Southern blot analysis requires a large
amount of genomic DNA (10 mg), is labor intensive, is
time-consuming, and may involve the use of hazardous
and/or radioactive chemicals.15
Newer PCR-based methods have been developed to
improve the detection of both large triplet repeat expansions, as well as the characterization of FMR1 methylation
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status. Triplet-repeat primer PCR can reliably detect all full
mutation alleles. The incorporation of capillary electrophoresis after triplet-repeat primer PCR facilitates the accurate
repeat size determination up to approximately 200
repeats.16,17 In addition, this technique enables the detection
of mosaic and apparently homozygous females, because it
ensures that normal allele does not outcompete the
expanded allele during the ampliﬁcation.1 A more costeffective screening platform using direct triplet-repeat
primer PCR with melting curve analysis was recently proposed.18 This method could be used as a ﬁrst-tier screen to
identify triplet repeat expansion carriers. In addition,
methylation-speciﬁc PCR techniques have been used in the
diagnosis of FXS, including quantitative methylationsensitive PCR,19 methylation-speciﬁc melting curve analysis,20
and
methylation-speciﬁcequantitative
melt
analysis.21
Herein, we describe a highly sensitive, cost-effective,
genome-wide DNA methylation screening technology that
is capable of reliably screening for FXS. In addition to
screening for FXS, this DNA methylation assay allows for
comprehensive methylation screening across the entire
genome, and can be useful as a supplement to copy number
microarray analysis and gene/genome sequencing. Specifically, in addition to screening for FXS, this assay also
enables simultaneous sensitive and speciﬁc screening for
Prader-Willi syndrome (PWS) as well as for Sotos syndrome, which are the two conditions most commonly
considered in the differential diagnosis of FXS.22 The advantages of this method make it applicable for routine use in
molecular diagnostic laboratories and screening programs,
as part of the more comprehensive testing repertoire in
families where FXS is ultimately identiﬁed.

Materials and Methods
Subjects and Blood Collection
Peripheral blood DNA samples were collected from patients
referred for FXS genetic testing at the Greenwood Genetic
Center. All patients were consented and counseled for FXS
testing as part of their clinical referral. Genomic DNA was
extracted from peripheral blood using standard techniques,
and CGG repeat size was determined by the Molecular
Diagnostic Laboratory at the Greenwood Genetic Center
using the PCR protocol described by Fu et al,23 with
modiﬁcations based on the information reported by
Houdayer et al.24 In addition, a commercially available
assay from Abbott Molecular (Des Plaines, IL) was used to
detect the presence of FMR1 expansion mutations of all
sizes.25 To conﬁrm the presence of trinucleotide expansion
within the FMR1 locus, samples were also subjected to
restriction enzyme digestion, followed by Southern blot
analysis using the DNA probe, StB12.3. Based on CGG
repeat size, our samples were grouped as follows: i) males
with FM, ii) males with PM, iii) males with mosaicism
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(mosaic-FM; FMþ normal/PM allele), iv) FM heterozygous
females, and v) PM females.

Methylation Array and Data Analysis
DNA methylation analysis was performed using the Illumina
HumanMethylation450 microarray (San Diego, CA), according to the standard protocol at the Genetic and Molecular
Epidemiology Laboratory at McMaster University. In addition to the FMR1 promoter, this array covers approximately
485,000 human genomic methylation CpG sites, including
99% of RefSeq genes and 96% of CpG islands. Methylation
data were converted to .idat ﬁles using Genome Studio software version 2011.1 (Illumina, Victoria, BC, Canada), and
imported into Partek Genomic Suite software version 6.6 (St.
Louis, MO) for analysis. Initial analyses were generated by
comparing the following groups: i) all FXS males (FM and
FM-mosaic; n Z 32) versus male controls (n Z 210),
ii) mosaic-FM males (n Z 9) versus male controls, iii)
mosaic-FM males versus FM males (n Z 23), iv) FM females
(n Z 5) versus female controls (n Z 151), and v) PM males
(n Z 11) and PM females (n Z 11) versus sex-matched
controls. Analysis of variance test was performed to
generate a probe-level statistical analysis, including P value
(t-test), F value (signal to noise), and estimate (net methylation difference). Genomic regions with signiﬁcant DNA
methylation patterns were identiﬁed that met the following
statistical criteria: i) a minimum of three consecutive probes
with probe-level differential methylation P < 0.01, ii) a mean
F value across the region >50, and iii) an estimate value
>0.15 (15% increase or decrease in methylation). Signiﬁcant regions were mapped against the CpG islands and gene
promoter regions. Last, regions with most signiﬁcant
methylation changes, including the FMR1 locus, were ﬁltered
and annotated in respect to their distance to CpG islands and
gene promoters. Data were visualized using Partek Genomic
Suite genomic browser, and individual probes at the FMR1
promoter region were tested for statistical differences
between FXS FM, mosaics, and controls.

Results

premutation had repeats ranging from 55 to 160
(Supplemental Table S1). Female patients included ﬁve with
FM and 11 premutation carriers (Supplemental Table S2).
Genome-wide DNA methylation analysis of all males with
FXS revealed hypermethylation at the FMR1 promoter site
within the CpG island (Figure 1, AeC). This included signiﬁcant hypermethylation at a 1482-bp region containing 13
probes within the FMR1 promoter (P Z 0.0000446,
estimate Z 0.66, and F Z 1883). Average methylation level
across this region was 0.75 (SD Z 0.19) and 0.09
(SD Z 0.01) for males with FXS and male controls, respectively (Supplemental Table S3). At a methylation level cutoff
of 0.2 (20%), the sensitivity and speciﬁcity of the methylation
array to detect FXS patients in this study was 100%
(Figure 2A). All FM males had a robust hypermethylation
(0.84; SD Z 0.10), whereas males with mosaicism exhibited a
relative attenuation of methylation signal (0.54; SD Z 0.21)
(Figure 1, AeC, and Supplemental Table S3). The size of the
repeat in nonmosaic FM males did not appear to correlate with
the extent of methylation (Supplemental Figure S1), but was
consistent with near complete methylation across the CpG
island. Statistically signiﬁcant hypermethylation in FXS male
patients was evident across all 13 probes (P < 0.01)
(Supplemental Figure S2). In patients with mosaic-FM FMR1
mutation, statistically signiﬁcant hypermethylation at a
single-probe level was also evident, albeit at lower levels than
in the FM patients (P < 0.01) (Supplemental Figure S2).
Females with one FM allele, including one female with mild
intellectual disability and one female with behavioral problems, did not show differential methylation at the FMR1 locus
compared to control females (Figure 1, D and E, Figure 2B,
and Supplemental Table S4). Similarly, the presence of a
premutation at FMR1 was not associated with changes in
FMR1 methylation in both males and females (Figure 1, A and
D). These results demonstrate the ability of genome-wide
methylation array to identify FM FXS males with 100%
sensitivity and speciﬁcity, as well as to effectively differentiate mosaic-FM patients from controls or FM patients, as
visualized either across the FMR1 promoter as a whole
(Figure 1, B and D) or at a single probe resolution
(Supplemental Figure S2). Signiﬁcant methylation changes
were not observed in female with full mutation (Figure 1E).

FMR1 Methylation Analysis in the FXS Patients
Genomic DNA Methylation Analysis in the FXS Patients
To assess the ability to discern differential methylation levels
at the FMR1 gene promoter, we ﬁrst compared DNA
methylation levels in control, non-FXS males and females
(Figure 1). Control males showed hypomethylation at the
promoter CpG island of the FMR1 gene, whereas females,
with one inactive X chromosome, showed hemimethylation
(approximately 50% methylation) at this locus (P < 0.01,
estimate Z 0.31, and F Z 1310). Trinucleotide CGG repeat
size from the 32 males with FXS ranged from 200 to 2000
repeats, nine (28%) of whom also showed mosaicism with the
expanded triplet repeat allele and a premutation or a normal
allele (Supplemental Table S1). Eleven males with

In addition to assessment of the FMR1 locus, genome-wide
DNA methylation screening allows for the concurrent identiﬁcation of additional aberrant methylation loci across the
genome, including >99% of gene promoters and all known
imprinted loci. Genomic methylation analysis of each FXS
male also showed some locus-speciﬁc methylation changes
(Supplemental Table S5). As an example, one FXS male patient demonstrated hypermethylation of a CpG island overlapping the retinitis pigmentosa GTPase regulator-interacting
protein (RPGRIP1) gene (OMIM 605446) (Supplemental
Table S5). RPGRIP1 is associated with cone-rod dystrophy
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Figure 1 DNA methylation analysis of FMR1 promoter in FXS patients
versus controls. The ﬁgures show the methylation levels (0 Z 0%
methylation, 0.5 Z 50% methylation, 1 Z 100% methylation) at speciﬁc array probes at the FMR1 gene promoter; the CpG island location
(gray boxes); and the reference sequence (RefSeq) for 50 to 30 strand (þ)
and for 30 to 50 strand (). A: FMR1 mean methylation levels in males
with full mutation (FM; red), mosaic-FM (green), premutation (PM; blue),
and controls (black). B: Hypermethylation in FM FXS male patients (red)
compared to male controls (black): individual sample proﬁles.
C: Hypermethylation in mosaic-FM male patients (green) compared to
male controls (black): individual sample proﬁles. D: Mean methylation
levels in females with FMR1 FM allele (red) and PM (blue) compared to
female controls (black). E: Methylation levels in FM carrier females (red)
compared to female controls (black): individual sample proﬁles.

13 (OMIM 608194) and Leber congenital amaurosis 6 (OMIM
613826). Another FXS male individual showed hypermethylation at the CpG island in the promoter of the AKR7L
gene (OMIM 608478) (Supplemental Table S5). This gene
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encodes an aldo-keto reductase, which is involved in the
detoxiﬁcation of aldehydes and ketones. The clinical
signiﬁcance of these locus-speciﬁc hypermethylation/hypomethylation variants in these patients is unclear at this time.
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Figure 2

A: Mean methylation for all 13
probes at FMR1 gene promoter in male controls,
premutation males (PM), mosaicefull mutation
(FM), and FM FXS patients. A methylation value
cutoff of 0.2 enables accurate identiﬁcation of FXS
patients. B: Mean methylation for all 13 probes at
FMR1 gene promoter in female controls, PM, and
FM female carriers. ****P < 0.0001 (methylation
level is signiﬁcantly different).

Discussion
In this study, we have clinically validated a novel FXS
screening approach. We have demonstrated 100% sensitivity
of detecting affected males with full mutation and full mutation mosaicism. Although we did not observe methylation
differences in relation to the size of the FM expansion, this is
consistent with previous ﬁndings that show that only full
mutation alleles undergo promoter methylation with subsequent FMR1 gene silencing and loss of fragile X mental
retardation protein, and that the severity of FXS does not
appear to be correlated to the absolute size of the mutant
allele.12 Alternatively, affected mosaic-FM males tend to
have a less marked clinical phenotype, as well as higher intelligence quotient scores than those with fully methylated
alleles, which is attributed to residual expression of the fragile
X mental retardation protein.26 Mosaicism may occur both in
terms of repeat length and methylation status (methylation
mosaics). However, it is the level of DNA methylation at the
FMR1 promoter that equates to the percentage of cells with
loss of fragile X mental retardation protein expression. Our
ﬁndings demonstrate that this assay effectively distinguishes
mosaic-FM males from males with nonmosaic FXS. As
anticipated, this assay did not detect methylation differences
at the FMR1 promoter in females with a full mutation allele,
even though some of these females presented a mild phenotype of intellectual disability or behavior problems. This
corroborates previous ﬁndings that X chromosome inactivation, and consequently FMR1 promoter methylation, occurs
preferentially in the chromosome with the FMR1 mutated
allele.27 It was previously shown that in FM females, where
some elevation of the FMR1 methylation can be demonstrated, methylation status generally does not correlate with
clinical manifestation of the disease symptoms.19 In addition,
this assay is not able to detect FXS in the rare cases (<0.05%)
where the cause of FXS is deletion of the FMR1 gene in male
patients. However, in females, FMR1 deletion would be
detectable because of the loss of the hemimethylated proﬁle,
resulting in either hypermethylation or hypomethylation at
that locus, depending on whether the deletion is on the active
or the inactive X.

One clear advantage of this DNA methylation array
approach over PCR-based methods for FXS screening is the
genome-wide coverage of the assay, which enables the
identiﬁcation of additional locus-speciﬁc methylation
changes that may be associated with the patient phenotype
by acting as modiﬁers of the disease. A previous study that
compared nine FM FXS males with 53 controls using this
same methylation array has conﬁrmed the ability to detect
FMR1-speciﬁc methylation changes, but was unable to ﬁnd
common methylation changes beyond the FMR1 gene
locus.28 The group analysis on our larger cohort of 23 FM
males and nine mosaic FM males versus 210 controls has
corroborated the FMR1 methylation ﬁndings. In addition, in
some patients, we were able to demonstrate the existence of
unique patient-speciﬁc methylation changes in genes such
as AKR7L and RPGRIP1 (Supplemental Table S5) that may
have additional phenotypic consequences independent of
the FMR1 defects in each patient. A large reference cohort
enables more sensitive assessment for such patient-speciﬁc
changes, as we have previously demonstrated.29,30
Currently, there is little known about such gene-speciﬁc
DNA methylation changes, and how they may affect and/
or modify clinical presentation in individual patients.
Expanding the databases of DNA methylation proﬁles in
patients with deﬁned and distinct clinical phenotypes will
enable us to differentiate recurrent clinically signiﬁcant
DNA methylation defects from nonpathogenic epigenetic
polymorphisms in a similar manner to which DNA copy
number assessment evolved using microarrays over the
years.
In contrast, some genomic DNA methylation changes,
including imprinting defects and genetically caused episignatures, have a clearly deﬁned clinical association. Two
disorders that are most commonly considered in the differential diagnosis of FXS because of the similar clinical
presentation, Sotos syndrome and PWS,22 possess unique
DNA methylation signatures. Diagnosis of PWS involves
DNA-based methylation testing to detect abnormal parentspeciﬁc loss of imprinting within the Prader-Willi critical
region at the SNRPN gene locus on chromosome 15.31 Sotos
syndrome is caused by loss-of-function mutations of the
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NSD1 gene, which has recently been shown to result in a
highly sensitive and speciﬁc DNA methylation signature
across multiple genomic loci.32 In Figure 3, we demonstrate
the ability of this DNA methylation array to detect
methylation defects at the SNRPN locus associated with
PWS and its reciprocal imprinting condition Angelman
syndrome (Figure 3A), as well as deﬁning two representative DNA methylation signature loci associated with Sotos
syndrome (Figure 3B). These data demonstrate that in
addition to FXS screening, the DNA methylation assay we
have described can be used as a concurrent test for the
differential diagnoses of PWS and Sotos syndrome in these
patients.
Because most families with FXS are ascertained
through the diagnosis in the affected male probands, this
DNA methylation array can be implemented as a primary
screen, thereby replacing costly, potentially hazardous,
and labor-intensive Southern blots and long-range PCR

assays. In the small percentage of families in which FXS
is detected (<1%), the more complex trinucleotide analysis assays can be used for further testing and risk
assessment in matrilineal relatives. Similarly, in patients
who are shown to have a DNA methylation signal
consistent with PWS or Sotos syndrome, follow-up molecular and cytogenetic testing may be warranted.
Therefore, this assay is meant to be used as a screening
tool to identify families with FXS, where male probands
are identiﬁed with the clinical features. Because it is the
males who present with more severe phenotypes, they are
more commonly to be identiﬁed ﬁrst in these families.
The assay, however, is not meant to replace further
molecular workup, including the assessment of the repeat
size and the identiﬁcation of possible premutation. Also,
the assay is not meant to identify the full mutation carrier
females, affected or not. Because of the preferential
skewing of the X-inactivation to the abnormal

Figure 3

Differential DNA methylation analysis using genome-wide
methylation array. The ﬁgures show the methylation levels (0 Z 0%
methylation, 0.5 Z 50% methylation, 1 Z 100% methylation); the CpG
island location (gray boxes); and the reference sequence (RefSeq) for 50
to 30 strand (þ) and for 30 to 50 strand (). A: DNA methylation pattern
at SNRPN locus on chromosome 15 in patients with Prader-Willi syndrome
(red) and Angelman syndrome (blue). B: Episignature in patients with
Sotos syndrome; two patients (blue and red) show similar DNA methylation changes at two loci on chromosome 6 when compared with controls
(black). Both genes have recently been described as part of the unique
Sotos episignature.32
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X chromosome, and possibility of differential skewing
patterns in the different tissues, full mutation females may
not show differential methylation at the FMR1 locus in
peripheral blood. Two of the females tested in our cohort
have been conﬁrmed to have mild cognitive
and behavioral abnormalities, and did not show any
abnormal DNA methylation pattern, including at the
FMR1 locus.
In a similar manner to the way in which cytogenetic
microarray testing has largely replaced single copy number
analyses, such as ﬂuorescence in situ hybridization, for
diagnosis of constitutional genetic disorders in the past
decade, genome-wide DNA methylation screening has a
potential to displace many of the known epigenetic single
analyte tests. Our laboratory has validated this assay for
sensitive and speciﬁc detection of all known imprinting
disorders, including PWS, Angelman syndrome, BeckwithWiedemann syndrome, and Russell-Silver syndrome (data
not shown). Furthermore, genome-wide DNA methylation
screening will enable parallel screening of genetic conditions associated with DNA methylation episignatures. In
addition to the previously described episignatures Sotos
syndrome32 and the X-linked intellectual disability caused
by the KDM5C gene,33 our laboratory has recently
demonstrated unique DNA methylation signatures in
patients with three other conditions, including FloatingHarbor syndrome (R.L. Hood et al, unpublished data),
caused by mutation in the SRCAP gene, cerebellar ataxia,
and deafness, narcolepsy syndrome (K.D. Kernohan et al,
unpublished data), caused by mutations in the DNMT1 gene,
and X-linked a-thalassemia/mental retardation, caused by
mutation in the ATRX gene (L.C. Schenkel et al, unpublished data). Analogous to the clinical cytogenetic microarray screening, as new epigenetic signatures become
deﬁned, utility of genome-wide DNA methylation screening
is expected to evolve beyond single-disorder testing to
encompass multidisorder screening. Utilization of this
technology in routine clinical practice will enable the discovery of new epigenetic biomarkers and will enhance our
understanding of human disease etiology, but will also
potentially yield many ﬁndings that we currently are not
able to clinically interpret. Identiﬁcation of such epigenetic
variants of unknown clinical signiﬁcance will require delivery of testing to be performed in regulated clinical laboratories, the development and implementation of clinical
and laboratory testing guidelines, and availability and integration with pretest and post-test genetic counseling.
In conclusion, we have demonstrated a genome-wide
DNA methylation approach for sensitive and speciﬁc
screening of patients with clinical features of FXS, as a costand labor-effective alternative to the currently used monogenic testing approaches. Moreover, this assay enables
concurrent assessment of disorders commonly considered as
the differential diagnosis for FXS, including Sotos
syndrome and PWS, along with other imprinting syndromes
and constitutional genetic disorders associated with

episignatures. Therefore, the use of genome-wide DNA
methylation array as a ﬁrst-line testing will not only allow
the identiﬁcation of a broad range of known genetic
conditions, but will also provide genome-wide information
on the DNA methylation patterns in patients with complex
phenotypes.
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